MARY1

MARY1 is a novel, potent, and subtype-selective antagonist of the serotonin-2B receptor (5-HT2B receptor). It is a small molecule from the pyridinylpiperazine class. MARY1 induces mitochondrial biogenesis (MB) in renal tissue by activating both the PI3K/AKT and RAS/MEK/ERK pathways, resulting in upregulation of PGC-1α and associated mitochondrial and β-oxidation proteins. In preclinical studies, MARY1 administration after ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) in mice and rats improved renal function, restored mitochondrial homeostasis, vascular integrity, and promoted autophagy. MARY1 represents a potential mitochondria-targeted therapy for acute kidney injury and related mitochondrial dysfunction–associated renal diseases.[1][2]